By Abigail Townsend
Date: Wednesday 04 Feb 2026
(Sharecast News) - Shares in Novo Nordisk opened sharply lower on Wednesday, after the obesity drug specialist warned of thinning sales and profits.
The Ozempic manufacturer said the global GLP-1 market was expected to grow in the current year, while new treatments include higher doses and a pill version of...
or login to read the full story
Email this article to a friend
or share it with one of these popular networks:
You are here: news